Recent landmark trials, particularly the SELECT study, have provided compelling evidence for cardiovascular benefits in non-diabetic obese patients, potentially reshaping our understanding of obesity treatment paradigms
Slowing down gives the signal time to arrive and reduces the air you take in
Light exposure: tirzepatide degrades under UV light
Thats exactly who should be getting this therapy. Targeting Alstrm Syndrome In Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alstrm Syndrome, a Rare Obesity Syndrome , published in JCEM in April, Thomas Scherer, MD, of the Medical University of Vienna, in Vienna, Austria, and team showed tirzepatides efficacy even in the particularly difficult-to-treat Alstrm syndrome (AS), a rare, genetic, multisystemic disorder, characterized by, among other conditions, diabetes with profound insulin resistance due to marked hyperphagia
That is roughly 16 months of treatment
In orthopedic and sports medicine applications, GHK-Cu may be considered to support: Soft tissue repair, Collagen synthesis, Joint and connective tissue health, Post-injury tissue remodeling, Inflammatory modulation